Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study

Fig. 3

RA endpoints following the administration of tofacitinib in RA patients with T2D. The administration of tofacitinib induced an improvement of RA disease activity; a significant reduction was observed in values of DAS28-CRP, SDAI, C reactive protein, evaluator global disease assessment, patient global disease assessment, and VAS pain. At baseline, 40 patients were evaluated, 37 after 3 months, and 32 after 6 months, respectively. A DAS28, Disease Activity Score using 28 joints; B SDAI, simplified disease activity score; C CRP, C-reactive protein; D ESR, erythrocyte sedimentation rate; E evaluator global assessment; F patient global disease assessment; G VAS, Visual Analogue Scale; H HAQ-DI, Health Assessment Questionnaire Disability Index

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us